Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D
On October 26th, 2021
October 22, 2021 Subject: Voluntary withdrawal of PEPAXTO® (melphalan flufenamide) for the treatment of relapsed or refractory multiple myeloma
Dear Healthcare Provider: This letter is to inform you about important information regarding PEPAXTO in the United States. On October 22, 2021, Oncopeptides announced the decision to voluntarily withdraw the US accelerated approval for PEPAXTO in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. You can read the press release here. This decision was made following consultation with the U.S. Food and Drug Administration (FDA) regarding the results of the Phase 3 OCEAN study, which showed an overall survival in the intent-to-treat population with a hazard ratio of 1.104. Prescriber Action At this time, no new patients should begin taking PEPAXTO. If a patient is currently taking PEPAXTO and they are receiving a benefit, Oncopeptides is committed to keeping PEPAXTO available to them free of charge and is working with FDA to ensure appropriate patients have access to treatment. Please contact OnCourse Patient Support Services at 1-844-300-ONCO (1-844-300-6626) for additional information. Please consult with your billing/reimbursement practice staff to understand reimbursement considerations regarding PEPAXTO during this time of transition. Please contact your specialty distributor with respect to questions regarding the returned goods policy applicable to PEPAXTO. Company Contact Point If you have any further questions about the information contained in this letter, please contact Oncopeptides Medical Information at 1-866-522-8894.
October 22, 2021 Subject: Voluntary withdrawal of PEPAXTO® (melphalan flufenamide) for the treatment of relapsed or refractory multiple myeloma
Dear Healthcare Provider: This letter is to inform you about important information regarding PEPAXTO in the United States. On October 22, 2021, Oncopeptides announced the decision to voluntarily withdraw the US accelerated approval for PEPAXTO in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. You can read the press release here. This decision was made following consultation with the U.S. Food and Drug Administration (FDA) regarding the results of the Phase 3 OCEAN study, which showed an overall survival in the intent-to-treat population with a hazard ratio of 1.104. Prescriber Action At this time, no new patients should begin taking PEPAXTO. If a patient is currently taking PEPAXTO and they are receiving a benefit, Oncopeptides is committed to keeping PEPAXTO available to them free of charge and is working with FDA to ensure appropriate patients have access to treatment. Please contact OnCourse Patient Support Services at 1-844-300-ONCO (1-844-300-6626) for additional information. Please consult with your billing/reimbursement practice staff to understand reimbursement considerations regarding PEPAXTO during this time of transition. Please contact your specialty distributor with respect to questions regarding the returned goods policy applicable to PEPAXTO. Company Contact Point If you have any further questions about the information contained in this letter, please contact Oncopeptides Medical Information at 1-866-522-8894.
No comments have been posted yet.